Kar S, et al. - Researchers report findings of 5 years of follow-up in patients who had transcatheter mitral valve (MV) repair with the MitraClip for mitral regurgitation (MR) 3+ or 4+ in the Endovascular Valve Edge-to-Edge Repair (EVEREST) II High Risk Study (HRS). Findings demonstrated a decline in the rate of postprocedural adverse events from 30 days to 1-year follow-up, which remained stable thereafter through 5 years. Based on the findings of the EVEREST II HRS, MitraClip was proved to be safe as well as efficacious in high-surgical-risk patients long-term (5 years). The advanced age and comorbidity profile of the patients most likely accounted for the observed mortality. Through long-term follow-up, durable improvements in New York Heart Association (NYHA) class were seen in surviving patients.